Monitoring Molecular Response to TKI Therapy in Chronic Myelogenous Leukemia

This information was originally presented on March 15, 2014, at the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

Target Audience

This activity is designed to meet the educational needs of physicians, nurses, pharmacists, and other clinical professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Integrate into professional practice the key updates of the NCCN Guidelines related to chronic myelogenous leukemia
  • Explain the rationale, methodology, and recommendation for monitoring molecular response to TKI therapy using QPCR (IS)
  • Utilize the results of molecular monitoring and mutational analysis to select the appropriate TKI therapy
Additional information

Supported by educational grants from:

  • Bristol-Myers Squibb
  • Novartis Oncology
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Oncology

Supported by a grant from:

  • Onyx Pharmaceuticals
Course summary
Available credit: 
  • 0.75 Participation
  • 0.85 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician
Course opens: 
Course expires: 

Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Available Credit

  • 0.75 Participation
  • 0.85 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician


Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader for certificate viewing/printing